CSX Corp

CSX remains in a Stage 2 advancing regime within a long-term uptrend, but price is extended above the rising EMAs and at extreme overbought levels, increasing pullback risk. Under the Stable strategy framework, execution is deferred and we will stalk for a meaningful retracement into the 9 and 21 EMA support zone before initiating new exposure.

• ↑Operating income rose 20% to $850 mn and EPS jumped 26% to $0.95.
• ↑Management now targets mid-single-digit revenue growth for FY26.
• ↓Negative earnings yield and weak profitability signal strained margins.